Is dabigatran etexilate capsules (Pradaxa) covered by medical insurance?

Dabigatran etexilate capsules (Pradaxa)The original drug has been launched in China and is sold under the name of dabigatran etexilate capsules (Pradaxa). It has also passed the relevant regulations of the National Medical Insurance Bureau and entered the scope of Class B medical insurance reimbursement. Dabigatran etexilate is indicated in adults to reduce the risk of stroke and systemic embolism associated with nonvalvular atrial fibrillation and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients receiving parenteral anticoagulants for 5 to 10 days. It is also indicated in adults to reduce the risk of deep vein thrombosis and pulmonary embolism in previously treated patients and to prevent deep vein thrombosis and pulmonary embolism in patients who have undergone hip replacement surgery.